The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 11327595 |
4 |
Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. |
Celltech R&D |
| 27301679 |
21 |
Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket. |
Takeda Pharmaceutical |
| 26789933 |
100 |
Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases. |
Intra-Cellular Therapies |
| 25264825 |
54 |
Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors. |
Centro De Investigaciones Biol�Gicas (Csic) |
| 22780914 |
35 |
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. |
Pfizer |
| 22944118 |
27 |
Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model. |
Glenmark Pharmaceuticals |
| 22487174 |
36 |
Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation. |
Glenmark Pharmaceuticals |
| 15887951 |
29 |
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. |
Monash University (Parkville Campus) |
| 21955943 |
47 |
Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region. |
Pfizer |
| 21087867 |
30 |
Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors. |
Universit£ |
| 20450197 |
80 |
Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors. |
Biotie Therapies |
| 20196613 |
32 |
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5). |
Pfizer |
| 19631533 |
126 |
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one. |
Pfizer |
| 19919087 |
55 |
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. |
Pfizer |
| 19339180 |
69 |
The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. |
Pfizer |
Search and Browse
